nach oben

Erschienen in:

01.06.2016 | ASNC IMAGING GUIDELINES

ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers

verfasst von: Milena J. Henzlova, MD, W. Lane Duvall, MD, Andrew J. Einstein, MD, Mark I. Travin, MD, Hein J. Verberne, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

Exercise testing has been used for more than 60 years for diagnostic purposes in symptomatic patients [including patients with acute chest pain without ischemia by electrocardiogram (ECG) and serum markers] and for prognosis and risk stratification in patients with known coronary artery disease (CAD), such as history of myocardial infarction or documented CAD by coronary angiography or computed tomography angiography and in those with high risk for the presence of CAD, such as patients with diabetes mellitus, peripheral, or cerebral vascular disease. …

Nur mit Berechtigung zugänglich

Myers J, Arena R, Franklin B, Pina I, Kraus WE, McInnis K, et al. Recommendations for clinical exercise laboratories: A scientific statement from the American Heart Association. Circulation 2009;119:3144-61.PubMedCrossRef

Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise standards for testing and training: A scientific statement from the American Heart Association. Circulation 2013;128:873-934.PubMedCrossRef

Myers J, Forman DE, Balady GJ, Franklin BA, Nelson-Worel J, Martin BJ, et al. Supervision of exercise testing by nonphysicians: A scientific statement from the American Heart Association. Circulation 2014;130:1014-27.PubMedCrossRef

Mieres JH, Gulati M, Bairey Merz N, Berman DS, Gerber TC, Hayes SN, et al. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: A consensus statement from the American Heart Association. Circulation 2014;130:350-79.PubMedCrossRef

Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: Executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Nucl Cardiol 2015;22:162-215.PubMedCrossRef

Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician’s guide to cardiopulmonary exercise testing in adults: A scientific statement from the American Heart Association. Circulation 2010;122:191-225.PubMedCrossRef

Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1-23; quiz 101-102.PubMedCrossRef

Zoghbi GJ, Dorfman TA, Iskandrian AE. The effects of medications on myocardial perfusion. J Am Coll Cardiol 2008;52:401-16.PubMedCrossRef

Dilsizian VGH, Gewirtz H, Paivanas N, Kitsiou AN, Hage FG, Crone NE, et al. Serious and potentially life 1735 threatening complications of cardiac stress testing: Physiological 1736 mechanisms and management strategies. J Nucl Cardiol 2015;1737(22):1198-213.CrossRef

10.

Bokhari S, Ficaro EP, McCallister BD Jr. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol 2007;14:415-6.PubMedCrossRef

11.

Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results from the adenoscan multicenter trial registry. J Am Coll Cardiol 1994;23:384-9.PubMedCrossRef

12.

Thomas GS, Miyamoto MI. Should simultaneous exercise become the standard for adenosine myocardial perfusion imaging? Am J Cardiol 2004;94:3D-10D; discussion 10D-11D.PubMedCrossRef

13.

Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.PubMedCrossRef

14.

Agarwal V, DePuey EG. Regadenoson and seizures: A real clinical concern. J Nucl Cardiol 2014;21:869-70.PubMedCrossRef

15.

Page RL 2nd, Spurck P, Bainbridge JL, Michalek J, Quaife RA. Seizures associated with regadenoson: A case series. J Nucl Cardiol 2012;19:389-91.PubMedCrossRef

16.

Cabrera R, Husain Z, Palani G, Karthikeyan AS, Choudhry Z, Dhanalakota S, et al. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging. J Nucl Cardiol 2013;20:336-43; quiz 344-335.PubMedCrossRef

17.

Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective a(2a) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.PubMedCrossRef

18.

AlJaroudi WA, Alraies MC, Cerquiera MD, Jaber WA. Safety and tolerability of regadenoson in 514 SPECT mpi patients with and without coronary artery disease and submaximal exercise heart rate response. Eur J Nucl Med Mol Imaging 2013;40:341-8.PubMedCrossRef

19.

Parker MW, Morales DC, Slim HB, Karthikeyan AS, Choudhry Z, Dhanalakota S, et al. A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: A randomized controlled trial. J Nucl Cardiol 2013;20:185-96.PubMedCrossRef

20.

Ross MI, Wu E, Wilkins JT, Gupta D, Shen S, Aulwes D, et al. Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial. J Nucl Cardiol 2013;20:197-204.PubMedCrossRef

21.

Thompson RC, Patil H, Thompson EC, Thomas GS, Al-Amoodi M, Kennedy KF, et al. Regadenoson pharmacologic stress for myocardial perfusion imaging: A three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise. J Nucl Cardiol 2013;20:214-21; quiz 222-216.PubMedCrossRef

22.

Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al. Safety of dipyridamole testing in 73,806 patients: The multicenter dipyridamole safety study. J Nucl Cardiol 1995;2:3-17.PubMedCrossRef

23.

Candell-Riera J, Santana-Boado C, Castell-Conesa J, Aguadé-Bruix S, Olona M, Palet J, et al. Simultaneous dipyridamole/maximal subjective exercise with 99mtc-mibi SPECT: Improved diagnostic yield in coronary artery disease. J Am Coll Cardiol 1997;29:531-6.PubMedCrossRef

24.

Casale PN, Guiney TE, Strauss HW, Boucher CA. Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging. Am J Cardiol 1988;62:799-802.PubMedCrossRef

25.

Stern S, Greenberg ID, Corne RA. Quantification of walking exercise required for improvement of dipyridamole thallium-201 image quality. J Nucl Med 1992;33:2061-6.PubMed

26.

Vitola JV, Brambatti JC, Caligaris F, Lesse CR, Nogueira PR, Joaquim AI, et al. Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on tc-99m sestamibi imaging. J Nucl Cardiol 2001;8:652-9.PubMedCrossRef

27.

Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 1993;21:1583-90.PubMedCrossRef

28.

Marwick T, Willemart B, D’Hondt AM, Baudhuin T, Wijns W, Detry JM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mtc-mibi single photon emission computed tomography. Circulation 1993;87:345-54.PubMedCrossRef

29.

Johnston DL, Scanlon PD, Hodge DO, Glynn RB, Hung JC, Gibbons RJ. Pulmonary function monitoring during adenosine myocardial perfusion scintigraphy in patients with chronic obstructive pulmonary disease. Mayo Clin Proc 1999;74:339-46.PubMedCrossRef

30.

Reyes E, Loong CY, Wechalekar K, Latus K, Anagnostopoulos C, Underwood SR. Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2007;14:827-34.PubMedCrossRef

31.

Sundram F, Notghi A, Smith NB. Pharmacological stress myocardial perfusion scintigraphy: Use of a modified adenosine protocol in patients with asthma. Nucl Med Commun 2009;30:217-25.PubMedCrossRef

32.

Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36.PubMedCrossRef

33.

Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28.PubMedCrossRef

34.

Golzar Y, Doukky R. Regadenoson use in patients with chronic obstructive pulmonary disease: The state of current knowledge. Int J Chron Obstruct Pulmon Dis 2014;9:129-37.PubMedPubMedCentral

35.

Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.PubMedPubMedCentralCrossRef

36.

Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.PubMedCrossRef

37.

Aljaroudi W, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol 2011;18:90-5.PubMedCrossRef

38.

Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19:319-29.PubMedPubMedCentralCrossRef

39.

Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A. Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation. J Nucl Cardiol 2013;20:205-13.PubMedCrossRef

40.

Laighold S, Druz R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nucl Cardiol 2009;16:478-80.PubMedCrossRef

41.

Palani G, Husain Z, Salinas RC, Karthikeyan V, Karthikeyan AS, Ananthasubramaniam K. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol 2011;18:605-11.PubMedCrossRef

42.

Avakian SD, Grinberg M, Meneguetti JC, Ramires JA, Mansur AP. SPECT dipyridamole scintigraphy for detecting coronary artery disease in patients with isolated severe aortic stenosis. Int J Cardiol 2001;81:21-7.PubMedCrossRef

43.

Demirkol MO, Yaymaci B, Debes H, Basaran Y, Turan F. Dipyridamole myocardial perfusion tomography in patients with severe aortic stenosis. Cardiology 2002;97:37-42.PubMedCrossRef

44.

Kupari M, Virtanen KS, Turto H, Viitasalo M, Mänttäri M, Lindroos M, et al. Exclusion of coronary artery disease by exercise thallium-201 tomography in patients with aortic valve stenosis. Am J Cardiol 1992;70:635-40.PubMedCrossRef

45.

Burgstahler C, Kunze M, Gawaz MP, Rasche V, Wöhrle J, Hombach V, et al. Adenosine stress first pass perfusion for the detection of coronary artery disease in patients with aortic stenosis: A feasibility study. Int J Cardiovasc Imaging 2008;24:195-200.PubMedCrossRef

46.

Patsilinakos SP, Kranidis AI, Antonelis IP, Filippatos G, Houssianakou IK, Zamanis NI, et al. Detection of coronary artery disease in patients with severe aortic stenosis with noninvasive methods. Angiology 1999;50:309-17.PubMedCrossRef

47.

Patsilinakos SP, Spanodimos S, Rontoyanni F, Kranidis A, Antonelis IP, Sotirellos K, et al. Adenosine stress myocardial perfusion tomographic imaging in patients with significant aortic stenosis. J Nucl Cardiol 2004;11:20-5.PubMedCrossRef

48.

Samuels B, Kiat H, Friedman JD, Berman DS. Adenosine pharmacologic stress myocardial perfusion tomographic imaging in patients with significant aortic stenosis. Diagnostic efficacy and comparison of clinical, hemodynamic and electrocardiographic variables with 100 age-matched control subjects. J Am Coll Cardiol 1995;25:99-106.PubMedCrossRef

49.

Cremer PC, Khalaf S, Lou J, Rodriguez L, Cerqueira MD, Jaber WA. Stress positron emission tomography is safe and can guide coronary revascularization in high-risk patients being considered for transcatheter aortic valve replacement. J Nucl Cardiol 2014;21:1001-10.PubMedCrossRef

50.

Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2012;60:434-80.PubMedCrossRef

51.

Giedd KN, Bokhari S, Daniele TP, Johnson LL. Sinus arrest during adenosine stress testing in liver transplant recipients with graft failure: Three case reports and a review of the literature. J Nucl Cardiol 2005;12:696-702.PubMedCrossRef

52.

Kovacs D, Pivonka R, Khosla PG, Khosla S. Effect of caffeine on myocardial perfusion imaging using single photon emission computed tomography during adenosine pharmacologic stress. Am J Ther 2008;15:431-4.PubMedCrossRef

53.

Bottcher M, Czernin J, Sun KT, Phelps ME, Schelbert HR. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med 1995;36:2016-21.PubMed

54.

Kubo S, Tadamura E, Toyoda H, Mamede M, Yamamuro M, Magata Y, et al. Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. J Nucl Med 2004;45:730-8.PubMed

55.

Lapeyre AC 3rd, Goraya TY, Johnston DL, Gibbons RJ. The impact of caffeine on vasodilator stress perfusion studies. J Nucl Cardiol 2004;11:506-11.PubMedCrossRef

56.

Salcedo J, Kern MJ. Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole. Catheter Cardiovasc Interv 2009;74:598-605.PubMedCrossRef

57.

Smits P, Aengevaeren WR, Corstens FH, Thien T. Caffeine reduces dipyridamole-induced myocardial ischemia. J Nucl Med 1989;30:1723-6.PubMed

58.

Smits P, Corstens FH, Aengevaeren WR, Wackers FJ, Thien T. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion. J Nucl Med 1991;32:1538-41.PubMed

59.

Aqel RA, Zoghbi GJ, Trimm JR, Baldwin SA, Iskandrian AE. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. Am J Cardiol 2004;93:343-6.PubMedCrossRef

60.

Hage FG, Iskandrian AE. The effect of caffeine on adenosine myocardial perfusion imaging: Time to reassess? J Nucl Cardiol 2012;19:415-9.PubMedCrossRef

61.

Reyes E, Loong CY, Harbinson M, Donovan J, Anagnostopoulos C, Underwood SR. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol 2008;52:2008-16.PubMedCrossRef

62.

Lee JC, Fraser JF, Barnett AG, Johnson LP, Wilson MG, McHenry CM, et al. Effect of caffeine on adenosine-induced reversible perfusion defects assessed by automated analysis. J Nucl Cardiol 2012;19:474-81.PubMedCrossRef

63.

Zoghbi GJ, Htay T, Aqel R, Blackmon L, Heo J, Iskandrian AE. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol 2006;47:2296-302.PubMedCrossRef

64.

Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (cvt-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49:369-75.PubMedCrossRef

65.

Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: A randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008;51:328-9.PubMedCrossRef

66.

Tejani FH, Thompson RC, Kristy R, Bukofzer S. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: A prospective, randomized, multicenter study. Int J Cardiovasc Imaging 2014;30:979-89.PubMedPubMedCentralCrossRef

67.

Depuey EG, Mahmarian JJ, Miller TD, Einstein AJ, Hansen CL, Holly TA, et al. Patient-centered imaging. J Nucl Cardiol 2012;19:185-215.PubMedCrossRef

68.

Fazel R, Gerber TC, Balter S, Brenner DJ, Carr JJ, Cerqueira MD, et al. Approaches to enhancing radiation safety in cardiovascular imaging: A scientific statement from the American Heart Association. Circulation 2014;130:1730-48.PubMedCrossRef

69.

Einstein AJ, Pascual TN, Mercuri M, Karthikeyan G, Vitola JV, Mahmarian JJ, et al. Current worldwide nuclear cardiology practices and radiation exposure: Results from the 65 country IAEA nuclear cardiology protocols cross-sectional study (INCAPS). Eur Heart J 2015;36:1689-96.PubMedPubMedCentralCrossRef

70.

Einstein AJ, Tilkemeier P, Fazel R, Rakotoarivelo H, Shaw LJ, American Society of Nuclear Cardiology. Radiation safety in nuclear cardiology-current knowledge and practice: Results from the 2011 American Society of Nuclear Cardiology Member Survey. JAMA Intern Med 2013;173:1021-3.PubMedCrossRef

71.

Einstein AJ, Berman DS, Min JK, Hendel RC, Gerber TC, Carr JJ, et al. Patient-centered imaging: Shared decision making for cardiac imaging procedures with exposure to ionizing radiation. J Am Coll Cardiol 2014;63:1480-9.PubMedPubMedCentralCrossRef

72.

DePuey EG, Bommireddipalli S, Clark J, Leykekhman A, Thompson LB, Friedman M. A comparison of the image quality of full-time myocardial perfusion SPECT vs wide beam reconstruction half-time and half-dose SPECT. J Nucl Cardiol 2011;18:273-80.PubMedCrossRef

73.

Duvall WL, Croft LB, Ginsberg ES, Einstein AJ, Guma KA, George T, et al. Reduced isotope dose and imaging time with a high-efficiency CZT SPECT camera. J Nucl Cardiol 2011;18:847-57.PubMedCrossRef

74.

Einstein AJ, Blankstein R, Andrews H, Fish M, Padgett R, Hayes SW, et al. Comparison of image quality, myocardial perfusion, and left ventricular function between standard imaging and single-injection ultra-low-dose imaging using a high-efficiency SPECT camera: The millisievert study. J Nucl Med 2014;55:1430-7.PubMedPubMedCentralCrossRef

75.

Machac J, Bacharach SL, Bateman TM, Bax JJ, Beanlands R, Bengel F, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol 2006;13:e121-51.PubMedCrossRef

76.

Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick EH, Churchwell KB, et al. Myocardial perfusion and function: Single photon emission computed tomography. J Nucl Cardiol 2007;14:e39-60.PubMedCrossRef

77.

Chang SM, Nabi F, Xu J, Raza U, Mahmarian JJ. Normal stress-only versus standard stress/rest myocardial perfusion imaging: Similar patient mortality with reduced radiation exposure. J Am Coll Cardiol 2010;55:221-30.PubMedCrossRef

78.

Duvall WL, Wijetunga MN, Klein TM, Razzouk L, Godbold J, Croft LB, et al. The prognosis of a normal stress-only tc-99m myocardial perfusion imaging study. J Nucl Cardiol 2010;17:370-7.PubMedCrossRef

79.

Gibson PB, Demus D, Noto R, Hudson W, Johnson LL. Low event rate for stress-only perfusion imaging in patients evaluated for chest pain. J Am Coll Cardiol 2002;39:999-1004.PubMedCrossRef

80.

Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 2004;11:587-602.PubMedCrossRef

81.

Haider N, Baliga RR, Chandrashekhar Y, Narula J. Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. JACC Cardiovasc Imaging 2010;3:71-5.PubMedCrossRef

82.

Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: What have we learnt clinically? Eur J Nucl Med 2000;27:1-6.PubMedCrossRef

83.

Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging 1986;1:96-103.PubMed

84.

Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129-32.PubMed

85.

Raffel DM, Wieland DM. Development of mibg as a cardiac innervation imaging agent. JACC Cardiovasc Imaging 2010;3:111-6.PubMedCrossRef

86.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective admire-hf (adreview myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 2010;55:2212-21.PubMedCrossRef

87.

Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.PubMed

88.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013;6:772-84.PubMedCrossRef

89.

Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: A prospective study. Heart 2001;86:656-60.PubMedPubMedCentralCrossRef

90.

Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial ¹²³I-metaiodobenzylguanidine (mIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.PubMedCrossRef

91.

Travin MI. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol 2013;20:128-43; quiz 146.PubMedCrossRef

92.

AlBadarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of admire-hf risk score in predicting serious arrhythmic events in heart failure patients: Incremental prognostic benefit of cardiac ¹²³I-mIBG scintigraphy. J Nucl Cardiol 2014;21:756-62; quiz 753-755, 763-755.CrossRef

93.

Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 mIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.PubMedCrossRef

94.

Klein T, Dilsizian V, Cao Q, Chen W, Dickfeld TM. The potential role of iodine-123 metaiodobenzylguanidine imaging for identifying sustained ventricular tachycardia in patients with cardiomyopathy. Curr Cardiol Rep 2013;15:359.PubMedPubMedCentralCrossRef

95.

Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33.PubMedCrossRef

96.

Miranda CH, Figueiredo AB, Maciel BC, Marin-Neto JA, Simoes MV. Sustained ventricular tachycardia is associated with regional myocardial sympathetic denervation assessed with ¹²³i-metaiodobenzylguanidine in chronic chagas cardiomyopathy. J Nucl Med 2011;52:504-10.PubMedCrossRef

97.

Mitrani RD, Klein LS, Miles WM, Hackett FK, Burt RW, Wellman HN, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993;22:1344-53.PubMedCrossRef

98.

Paul M, Schafers M, Kies P, Acil T, Schäfers K, Breithardt G, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging 2006;33:866-70.PubMedCrossRef

99.

Paul M, Wichter T, Kies P, Gerss J, Wollmann C, Rahbar K, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med 2011;52:1559-65.PubMedCrossRef

100.

Wichter T, Matheja P, Eckardt L, Kies P, Schäfers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in brugada syndrome. Circulation 2002;105:702-6.PubMedCrossRef

101.

Tomoda H, Yoshioka K, Shiina Y, Tagawa R, Ide M, Suzuki Y. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-q-wave myocardial infarction and unstable angina. Am Heart J 1994;128:452-8.PubMedCrossRef

102.

Watanabe K, Takahashi T, Miyajima S, Hirokawa Y, Tanabe N, Kato K, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med 2002;43:1476-81.PubMed

103.

Fallavollita JA, Canty JM Jr. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol 2010;17:1107-15.PubMedPubMedCentralCrossRef

104.

Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141-9.PubMedPubMedCentralCrossRef

105.

McGhie AI, Corbett JR, Akers MS, Kulkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1991;67:236-42.PubMedCrossRef

106.

Simoes MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 2004;25:551-7.PubMedCrossRef

107.

Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989;14:1519-26.PubMedCrossRef

108.

Bengel FM, Ueberfuhr P, Schiepel N, Nekolla SG, Reichart B, Schwaiger M. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med 2001;345:731-8.PubMedCrossRef

109.

Flotats A, Carrio I. Value of radionuclide studies in cardiac transplantation. Ann Nucl Med 2006;20:13-21.PubMedCrossRef

110.

Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003;9:384-91.PubMedCrossRef

111.

Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, et al. Regional abnormality of iodine-123-mIBG in diabetic hearts. J Nucl Med 1996;37:1985-90.PubMed

112.

Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M, et al. Prognostic value of cardiac i-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006;13:34-42.PubMedCrossRef

113.

Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-mIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.PubMed

114.

Sciammarella M, Gerson M, Buxton AE, Bartley SC, Doukky R, Merlino DA, et al. Model coverage policy: Myocardial sympathetic innervation imaging: Iodine-123 meta-iodobenzylguanidine (¹²³I-mIBG). J Nucl Cardiol 2015;22:804-11.PubMedCrossRef

115.

Jacobson AF, Lombard J, Banerjee G, Camici PG. ¹²³I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.PubMedCrossRef

116.

Agostini D, Carrio I, Verberne HJ. How to use myocardial ¹²³I-mIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009;36:555-9.PubMedCrossRef

117.

Carrio I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging 2010;3:92-100.PubMedCrossRef

118.

Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of ¹²³i-metaiodobenzylguanidine (mIBG) cardiac sympathetic imaging by the eanm cardiovascular committee and the european council of nuclear Cardiology Eur J Nucl Med Mol Imaging 2010;37:1802-12.PubMedCrossRef

119.

Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34(Suppl 1):S62-73.PubMedCrossRef

120.

Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (mibg). Nucl Med Commun 1992;13:513-21.PubMedCrossRef

121.

Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.PubMedCrossRef

122.

Jacobson A, Travin M. Impact of neuropsychiatric medications on cardiac uptake of ¹²³I- mIBG in heart failure subjects. J Nucl Med 2013;54:1708.

123.

Friedman NC, Hassan A, Grady E, Matsuoka DT, Jacobson AF. Efficacy of thyroid blockade on thyroid radioiodine uptake in ¹²³I-mIBG imaging. J Nucl Med 2014;55:211-5.PubMedCrossRef

124.

Chen J, Folks RD, Verdes L, Manatunga DN, Jacobson AF, Garcia EV. Quantitative i-123 mIBG SPECT in differentiating abnormal and normal mibg myocardial uptake. J Nucl Cardiol 2012;19:92-9.PubMedCrossRef

125.

Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: Supersensitivity that may be arrhythmogenic. Circulation 1987;75:877-87.PubMedCrossRef

126.

Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008-19.PubMedCrossRef

127.

Dobbeleir AA, Hambye AS, Franken PR. Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: Consequences for imaging with 123i-labelled compounds in clinical practice. Eur J Nucl Med 1999;26:655-8.PubMedCrossRef

128.

Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F, et al. Effect of collimator choice on quantitative assessment of cardiac iodine 123 mIBG uptake. J Nucl Cardiol 2003;10:623-32.PubMedCrossRef

129.

Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on ¹²³I-mIBG heart/mediastinum ratios: A phantom study. Eur J Nucl Med 2005;32:1100-7.CrossRef

130.

Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Optimized acquisition and processing protocols for i-123 cardiac SPECT imaging. J Nucl Cardiol 2006;13:251-60.PubMedCrossRef

131.

Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Improved quantification in 123i cardiac SPECT imaging with deconvolution of septal penetration. Nucl Med Commun 2006;27:551-8.PubMedCrossRef

132.

Inoue Y, Abe Y, Itoh Y, Asano Y, Kikuchi K, Sakamoto Y, et al. Acquisition protocols and correction methods for estimation of the heart-to-mediastinum ratio in ¹²³I-metaiodobenzylguanidine cardiac sympathetic imaging. J Nucl Med 2013;54:707-707.PubMedCrossRef

133.

Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, et al. Standardization of the heart-to-mediastinum ratio of ¹²³i-labelled-metaiodobenzylguanidine uptake using the dual energy window method: Feasibility of correction with different camera-collimator combinations. Eur J Nucl Med 2009;36:560-6.CrossRef

134.

Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: Effects of correction on normal databases and a multicentre study. Eur J Nucl Med 2012;39:113-9.CrossRef

135.

Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of i-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 2014;21:970-8.PubMedPubMedCentralCrossRef

136.

Bellevre D, Manrique A, Legallois D, Bross S, Baavour R, Roth N, et al. First determination of the heart-to-mediastinum ratio in i-123-mIBG cardiac adrenergic CZT imaging in patients with heart failure. A d-SPECT versus a-SPECT prospective study. Eur J Nucl Med Mol Imaging 2015;42:1912-9.PubMedCrossRef

137.

Rouzet F, De Paola Chequer R, Milliner M, BenAzzouna R, Mikail N, Askienazy S, et al. Comparison of mIBG heart-to-mediastinum ratio determined on conventional and cardiac CZT camera. J Nucl Med 2014;55(supplement 1):133.

138.

Strydhorst J, Wells RG, Ruddy T. Phantom validation of ¹²³I-mIBG imaging with a dedicated solid state SPECT camera. J Nucl Med 2014;55(supplement 1):1689.

139.

Gimelli A, Liga R, Giorgetti A, Genovesi D, Marzullo P. Assessment of myocardial adrenergic innervation with a solid-state dedicated cardiac cadmium-zinc-telluride camera: First clinical experience. Eur Heart J Cardiovasc Imaging 2014;15:575-85.PubMedCrossRef

140.

Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 mIBG imaging. J Nucl Cardiol 2011;18:82-9.PubMedCrossRef

141.

Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: A ¹²³I-mIBG scintigraphic study. J Nucl Med 2000;41:845-51.PubMed

142.

Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002;9:608-15.PubMedCrossRef

143.

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: A prospective study. J Am Coll Cardiol 2003;41:231-8.PubMedCrossRef

144.

Jacobson AF, Matsuoka DT. Influence of myocardial region of interest definition on quantitative analysis of planar ¹²³I-mIBG images. Eur J Nucl Med Mol Imaging 2013;40:558-64.PubMedCrossRef

145.

Veltman CE, Boogers MJ, Meinardi JE, Al Younis I, Dibbets-Schneider P, Van der Wall EE, et al. Reproducibility of planar (123)i-meta-iodobenzylguanidine (mIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging 2012;39:1599-608.PubMedPubMedCentralCrossRef

146.

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131i/¹²³I-metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:132-9.CrossRef

147.

Center for Science in the Public Interest. Caffeine content of food & drugs. 2014.Table containing the caffeine content of food and drugs. http://www.cspinet.org/new/cafchart.htm.

Titel: ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers
verfasst von: Milena J. Henzlova, MD
W. Lane Duvall, MD
Andrew J. Einstein, MD
Mark I. Travin, MD
Hein J. Verberne, MD
Publikationsdatum: 01.06.2016
Verlag: Springer US
Erschienen in: Journal of Nuclear Cardiology / Ausgabe 3/2016
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0387-x

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers

Excerpt

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

A quick glance at selected topics in this issue

Stress testing in patients with chronic kidney disease: The need for ancillary markers for effective risk stratification and prognosis

Exercise and Bayes’ Theorem: Some things never go out of style

It’s not all in the numbers

Erratum to: Assessment of left ventricular ejection fraction using low radiation dose computed tomography

Incidental focal myocardial 18F-FDG uptake indicating asymptomatic coronary artery disease

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie